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Abstract
The ex vivo induction of alloantigen-specific hyporesponsiveness by costimulatory pathway
blockade or exposure to immunoregulatory cytokines has been shown to inhibit proliferation, IL-2
production, and the GVHD capacity of adoptively transferred T-cells. We hypothesized that
inhibition of the intracellular NF-κB pathway in alloreactive T-cells, which is critical for T cell
activation events including IL-2 transcription, could lead to alloantigen hyporesponsiveness and
loss of GVHD capacity. We demonstrate that treatment of mixed lymphocyte reaction (MLR)
cultures with PS1145, a potent inhibitor of NF-κB activation, can induce T cell
hyporesponsiveness to alloantigen in primary and secondary responses while preserving in vitro
responses to potent mitogenic stimulation. GVHD lethality in recipients of ex vivo PS1145-treated
cells was profoundly inhibited. Parking of control- or PS1145- treated MLR cells in syngeneic
Rag−/− recipients resulted in intact contact hypersensitivity responses. However, GVHD lethality
capacity also was restored, suggesting that lymphopenic expansion uncoupled alloantigen
hyporesponsiveness. These results indicate that the NF-κB pathway is a critical regulator of
alloresponses and provide a novel small molecule inhibitor based approach that is effective in
preventing early post-transplant GVHD lethality but that also permits donor T cell responses to
recover after a period of lymphopenic expansion.
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Introduction
Graft-versus-host disease (GVHD) remains a significant cause of morbidity and mortality
following allogeneic hematopoietic cell transplantation (HCT). Despite conventional
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immunosuppressive approaches used to prevent GVHD, the incidence of clinically
significant acute GVHD remains high (30–75%), especially for recipients with matched
unrelated donors (1–4). While T cell depletion of the donor graft reduces GVHD lethality, it
can also result in increased relapse rate, graft failure, and susceptibility to opportunistic
infections (5–7). Thus, there is a clear need to develop new strategies that increase the safety
of allogeneic HCT without compromising immune reconstitution.
As an alternative to conventional therapies in which donor T-cells are either globally
suppressed in vivo by pharmacological agents or removed in vitro, alloreactive donor T-cells
may be specifically rendered hyporesponsive to host alloantigens prior to in vivo infusion.
Alloantigen-reactive T-cells are present in a low frequency and can be rendered
hyporesponsive when exposed to alloantigen-bearing cells in a mixed lymphocyte reaction
(MLR) under tolerizing conditions (8,9). Ex vivo tolerance induction strategies have shown
promise in limiting GVHD lethality in murine models and in human clinical trials (8–15).
During the process of tolerance induction, the remaining non-alloreactive T-cells, such as
anti-viral T-cells, are not functionally altered as tolerization requires T cell receptor (TCR)
ligation. Thus, ex vivo tolerance induction, may be used to prevent GVHD while leaving
donor T-cells that do not participate in GVHD available to respond to tumor and foreign
antigens.
A fully functional T cell response requires ligation of the antigen-specific TCR and the
additional supplementary or costimulatory signals typically provided by antigen-presenting
cells (APCs) (16). Following TCR ligation and CD28 costimulation of normal T cell
activation, T-cells become activated and produce IL-2 (16). Ex vivo tolerance induction
therapies are based on the observation that suboptimal TCR stimulation, which fails to
induce IL-2 gene transcription or cell cycle progression, will render such T-cells unable to
be restimulated by the same antigen (17–19). Previously described approaches for inducing
tolerance ex vivo for GVHD protection have relied on costimulatory blockade (9,10). The
biochemical connection between CD28 costimulation and IL-2 transcription is well defined,
as the promoter of the IL-2 gene contains a CD28 response element with binding sites for
several transcriptional regulators including NF-κB (20). Thus, pharmacologic blockade of
NF-κB signaling in TCR activated cells would mimic the signaling defect induced by
costimulatory blockade and serve as a direct means of tolerance induction in antigen-
activated alloreactive T-cells.
Activation and nuclear translocation of NF-κB via CD28-dependent pathways requires
phosphorylation of IκB by the IκB kinase (IKK) complex (21–26). Human mutations in IKK
complex genes result in several clinical manifestations, including T cell immunodeficiency
(27–29). Because this step is critical and non-redundant in the activation of NF-κB, we
chose to block NF-κB activation with PS1145, a small molecule inhibitor of IKK. PS1145
has previously been shown to inhibit NF-κB activation in multiple myeloma cells through
inhibition of IκB phosphorylation (30).
We hypothesized that treatment with PS1145 during activation of donor T-cells with
recipient alloantigen would result a reduced donor T cell capacity for causing GVHD, while
permitting responses to nominal antigen exposure. Our data supports this hypothesis and
identifies a critical role for NF-κB signaling during allogeneic T cell responses.
Furthermore, strategies that selectively the NF-κB pathway in pathogenic T-cells have
potential clinical application for the prevention of GVHD and other T cell mediated
diseases.
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B6.C.H2bm12/KhEg (bm12), CBySmn.CB17-PrkdcSCID/J (BALB/c SCID, B6.CB17-
PrkdcSCID/SzJ (B6 SCID), C3H SCID and B6.Rag-1−/− mice were purchased from The
Jackson Laboratory (Bar Harbor, ME). BALB/c SCID mice were bred with B6 SCID mice
to generate (BALB/c × B6 SCID) F1 (CB6F1) mice. BALB/c and C57BL/6 (B6) mice were
purchased from the National Institutes of Health (Bethesda, MD). All mice were housed in a
specific pathogen-free facility according to NIH guidelines.
Mixed lymphocyte reactions
CD4+ T-cells were isolated as previously described (31). Purity of CD4+ T-cells was
routinely ≥95%. Whole T-cells were isolated from lymph nodes using PE-labeled antibodies
for CD19, DX5 and γδ TCR followed by anti-PE bead incubation and magnetic bead
separation (Miltenyi Biotech, Bergisch-Gladbach, Germany). CD25+ T-cells were depleted
with PE-labeled anti-CD25 (PC61) mAb (Pharmingen), followed by incubation with anti-PE
beads (Miltenyi), and removal by MACS LS columns (Miltenyi). CD4+CD25− T cell purity
was ≥98%. Responder T-cells were mixed with irradiated (30 Gy), T- and NK-cell depleted
splenic stimulators, prepared as described previously (31). Responders and stimulators were
cultured at 37°C and 10% CO2 for 4–9 days at a final concentration of 0.57×106/mL in 24-
well plates (Costar, Acton, MA) in DMEM (BioWhittaker, Walkersville, MD) complete
media (32). 20 mM stocks of PS1145 (Millennium Pharmaceuticals, Cambridge, MA) were
prepared in dimethyl sulfoxide (DMSO) and added to cultures at final concentrations as
indicated. In some experiments, cells were pre-treated with 6 or 10 µM PS1145 for 30
minutes at 4°C and washed extensively before establishing cultures. To monitor primary and
secondary responses, 105 responders and stimulators per well were cultured in 96-well
round-bottom microtiter plates (Costar) and recombinant human IL-2 was added as indicated
(Amgen). In some experiments, In other experiments, dead and dying cells were removed
using an Annexin V microbead kit (Miltenyi). Where indicated, anti-CD3ε/anti-CD28 mAb-
coated microspheres (33) (Dr. Carl June, Philadelphia, PA) were used to stimulate recovered
T-cells after treatment with vehicle or PS1145 in a primary MLR culture. Cells were pulsed
with tritiated thymidine (1 µCi/well) (Amersham Life Sciences, Buckinghamshire, United
Kingdom) on the indicated days for 16 to 18 hours prior to harvesting and counted in the
absence of scintillation fluid on a β-plate reader (Packard Instrument Company, Meriden,
CT) and analyzed in at least triplicate.
CFSE staining and flow cytometry
Freshly purified T-cells were stained with 1 µM CFSE (Molecular Probes, Eugene, OR) at
room temperature for 2 minutes with shaking, followed by washing 2X with cold 2% FCS in
PBS. CD4 and CD8 mAbs were purchased from Pharmingen (San Diego, CA) and staining
was done according to manufacturer’s protocol. Determination of cell viability was
performed using Annexin V (Pharmingen) according to the manufacturer’s protocol. All
flow cytometric experiments were done using a FACSCalibur (Becton Dickinson, San Jose,
CA).
Confocal Microscopy
Purified CD4+ T-cells were stimulated with anti-CD3ε/anti-CD28 mAb-coated microspheres
at a 1:1 ratio for 24 hours. After washing, cells were dried on microscope slides with a
Cytospin 2 centrifuge (Shandon), fixed with 4% paraformaldehyde for 5 minutes and
permeabilized with 0.5% Tween for 15 minutes. After blocking for 30 minutes with 10%
normal donkey serum in PBS cells were stained with 1:50 rabbit anti-p65 mAb (Santa Cruz)
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for one hour at room temperature, washed, and incubated with Cy3-conjugated donkey anti-
rabbit mAb (1:500 in PBS/0.5% Tween). For acquisition, a Melles Griot 543 nm HeNe laser
and Olympus BX61 laser scan confocal microscope equipped with a 100x oil immersion
objective was used.
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extracts were prepared from day 7 MLR cultures, incubated with α-32P-labeled NF-
κB consensus sequence probe and EMSA was performed as previously described (34).
Induction of GVHD
To test B6 anti-bm12 CD4+ T cell tolerance induction, bm12 recipients were sublethally
irradiated (6 Gy total body irradiation (TBI)) and 105 freshly isolated B6 CD4+ T-cells or
105 viable day 7 cultured cells were injected into the lateral tail vein. To test Balb/c anti-B6
whole T cell tolerance induction, NK cell-depleted CB6 F1 SCID recipients were irradiated
(2.1 Gy TBI) and 105 viable day 5 cultured cells were injected into the lateral tail vein. NK
cell depletion was continued 2×/week throughout the experiment using a purified NK1.1
mAb (PK136, 10 µg/g).
Parking of MLR-cultured cells and assessment of immune responses
2 × 106 freshly isolated B6 CD4+ T-cells or day 7 B6 anti-bm12 control- or PS1145 (10
µM)-treated MLR cells were injected into B6.Rag-1−/−mice. After 30 days, mice were
sensitized with 0.15 ml 3% 4-ethoxymethylene-2-phenyloxazolone (oxazolone) (Sigma; St.
Louis, MO) in ethanol:acetone (3:1) on shaved thoracic and abdominal skin and then
rechallenged 6 days later on the right ear with 0.025 ml 1% oxazolone in acetone:olive oil
(4:1) to induce a contact hypersensitivity (CH) response (35). 24 and 96 hours after
challenge, swelling in the right ear was measured with a digital microcaliper (Fowler;
Newton, MA). In other studies, splenic CD4+ T-cells (3 × 104) were adoptively transferred
into 6 Gy TBI conditioned bm12 or NK-depleted, 1.6 TBI conditioned third party C3H
SCID recipients.
Statistics
Group comparisons were made by Student's t test. Survival data were analyzed by lifetable
methods and actuarial survival rates are shown. Probability (P) values < 0.05 were
considered significant.
Results
PS1145 inhibits NF-κB activation and proliferation of alloreactive T-cells in MLR cultures
PS1145 has been shown to be an inhibitor of the NF-κB pathway in tumor cells. To
determine the effect of various concentrations of PS1145 on NF-κB localization in primary
T-cells, we used confocal fluorescence microscopy to assess nuclear localization of NF-κB
following mitogenic stimulation in the presence or absence of PS1145. Nuclear localization
of p65, a subunit of NF-κB expressed in T-cells, was observed in anti-CD3/anti-CD28 mAb
stimulated CD4+ T-cells untreated or treated with 2 µM PS1145, but was inhibited at
concentrations greater than 6 µM as evidenced by increasing localization of p65 to the
cytoplasmic space (Figure 1A). To determine whether PS1145 could inhibit alloreactive T
cell responses in vitro, highly purified B6 CD4+ T-cells were cultured with T cell-depleted,
irradiated splenic stimulators from MHC class II-disparate bm12 mice in the presence of 2,
6, or 10 µM PS1145 or vehicle control (0.05% DMSO). As compared to a control without
vehicle, the vehicle alone had no effect on proliferation (data not shown). Whereas 2 µM
PS1145 did not significantly inhibit peak T cell proliferation, 6 and 10 µM PS1145 inhibited
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T cell proliferation at all time points measured during the 7 day primary MLR (Figure 1B).
Peak proliferation (at day 5) was inhibited by more than 86% for 6 µM treated cultures and
90% for 10 µM treated cultures. These data suggested a threshold effect for PS1145 of > 2
µM and ≤ 6 µM. Therefore, PS1145 concentrations of 6–10 µM were chosen for further
study. PS1145 treatment (10 µM) also significantly reduced the amount of the T cell effector
cytokines IL-2 and IFN-γ as well as cytokines released by activated APCs, including IL-6
and GM-CSF, in the supernatant of d5 MLR cultures (data not shown).
To verify that PS1145 treatment was functionally inhibiting NF-κB activity in MLR cultured
cells, EMSA was performed on nuclear extracts prepared from MLR cultured cells that had
been treated or not with PS1145 (10 µM). As shown in Figure 1C, binding of nuclear
extracts from PS1145-treated cultures to an NF-κB consensus sequence probe is
significantly less than that observed in vehicle-cultured cells. Similar amounts of nuclear
extracts of vehicle treated and PS1145-treated culture were loaded as shown by Coomassie
staining and Western blot of β-actin (figure 2C right panel).
Because the NF-κB pathway can regulate APC function, including the expression of MHC
and costimulatory molecules (36), experiments were performed to determine whether the
capacity of PS1145 to inhibit in vitro alloresponses was due to its effects on T-cells, APCs
or both. Prior to MLR cultures, responder and stimulator cells were pre-loaded separately
with PS1145 and then washed free of excess drug. Cell viability was unaffected by PS1145
pre-treatment (data not shown). PS1145 pre-treatment of responder or stimulator cells
resulted in inhibition of alloresponses at all time points observed (Figure 1D). Although no
significant differences between pretreatment of responder or stimulator cells alone were
observed on day 3, pre-treatment of APCs was modestly more potent at inhibiting
alloproliferation on days 5 and 7 of culture (Figure 1D). Maximal inhibition of the
alloresponse at all time points required pre-treatment of both responder and stimulator cells
prior to initiation of culture. These data indicate that PS1145 treatment has direct effects on
stimulator APCs and responder T-cells, and both effects are required for optimal MLR
inhibition.
PS1145 induces alloantigenic hyporesponsiveness as assessed in vitro
T-cells activated with suboptimal costimulation are hyporesponsive and remain
hyporesponsive upon restimulation. To determine whether inhibition of alloresponses in
primary CD4+ MLR cultures by PS1145 (6 µM) treatment would result in
hyporesponsiveness to alloantigen after restimulation, cells were recovered on day 7 of a
primary MLR (Figure 2A), extensively washed free of PS1145 or vehicle, and equal
numbers of viable cells were restimulated with freshly prepared allogeneic bm12 splenic
stimulators. Control cells responded vigorously to restimulation at levels that exceeded the
primary response and peaked on day 2, indicative of allopriming. In contrast, cells recovered
from PS1145-treated MLR cultures were profoundly hyporesponsive to alloantigen
restimulation (Figure 2B). At all time points measured, secondary alloresponses of PS1145-
treated cells were inhibited by at least 80% even when measured as late as 10 days of culture
(data not shown). Addition of exogenous IL-2 reversed tolerance in PS1145-treated CD4 T
cell MLR cultures on day 4 (Figure 2B). Since the restoration of proliferation of PS1145-
treated cells to alloantigen restimulation in the presence of exogenous IL-2 occurred later
than control cultured cells, these data suggest either that the precursor frequency of
responding CD4 T-cells was reduced or there was a time period during which PS1145
continued to exert its action after removal from primary cultures.
Because secondary alloresponses of PS1145-treated cells were potently inhibited, we sought
to determine whether PS1145-treated cells could respond to non-alloantigenic stimulation
through the TCR. Cells recovered from PS1145 or vehicle treated cultures were stimulated
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with anti-CD3ε/anti-CD28 mAb-coated beads. Although responses of PS1145-treated cells
to alloantigenic restimulation were inhibited (Figure 2B), PS1145-treated cells responded
vigorously to stimulation with anti-CD3ε and anti-CD28 mAbs (Figure 2C). These results
indicate that in vitro treatment of MLR cultured responder cells with PS1145 results in
potent CD4+ hyporesponsiveness upon alloantigen restimulation, while only modestly
reducing non-specific mitogenic responses.
To assess whether alloantigenic hyporesponsiveness by PS1145 treatment of CD4+ T cell
containing MLR cultures is similarly effective for MLR cultures initated with both CD4+
and CD8+ T-cells, similar experiments were performed using whole Balb/c T cell responders
and T cell-depleted irradiated B6 splenic stimulators. As shown in Figure 3A, primary MLR
responses were significantly inhibited in the presence of PS1145 (10 µM). Secondary MLR
cultures from day 5 vehicle treated primary cultures responded vigorously to alloantigen
restimulation, whereas PS1145-treated cultures showed significant reduction in proliferation
at early time points (days 2 and 3) with only low levels of proliferation by day 4 (Figure
3B). CD4 to CD8 ratios of control and PS1145-treated primary cultures were similar on day
5 (CD4 T-cells: 83% vs 85% and CD8 T-cells: 14% vs 12 % for vehicle and PS1145-treated
cultures, respectively). Interestingly, in contrast to CD4 T cell MLR cultures exogenous IL-2
could not restore proliferation of PS1145-treated whole T cell cultures to control
proliferation (Figure 2B). Although there was a modest early decrease in proliferative
responses to stimulation with anti-CD3ε and anti-CD28 mAbs as compared to controls, by
day 4 responses were comparable and peak response of the PS1145-treated cells achieved
levels of 92% of control responses (Figure 3C). Therefore despite the profound inhibition of
MLR responses, mitogenic responses were only modestly and transiently reduced. Thus,
PS1145 treatment of whole T cell containing MLR cultures resulted in alloantigen
hypoproliferation that was not restored by exogenous IL-2, suggesting immune deviation or
loss of alloreactive T-cells.
PS1145 preferentially induces hyporesponsiveness and apoptosis in antigen-activated T-
cells
To determine whether deletion of antigen-activated cells contributes to the observed
alloantigen hyporesponsiveness, we performed analysis of cell division and induction of
apoptosis by CFSE and Annexin V staining, respectively. Analysis of day 6 BALB/c anti-B6
MLR cultures indicated that more CD4+ and CD8+ cells had undergone multiple cell
divisions (CFSElo quadrants) in control cultures (43.5% and 68.8%, respectively), compared
to CD4+ and CD8+ cells in PS1145-treated cultures (15.5% and 24.9%, respectively) (Figure
4). Simultaneous Annexin V staining indicated that the proportion of apoptotic (Annexin
Vhi) CFSElo cells was higher in PS1145-treated cultures than control cultures (31.5% vs.
25.7% and 40.2% vs. 33.1% for CD4+ and CD8+ T-cells, respectively). Thus, PS1145 limits
cell division of alloreactive T-cells but also sensitizes antigen-activated CD4+ and CD8+ T-
cells to undergo deletion which likely results in a T cell population that is enriched for non-
alloreactive T-cells. Consistent with this hypothesis, the removal of dead and dying cells
using Annexin V microbeads prior to performing secondary MLR cultures did not restore
hypoproliferation of PS1145-treated T-cells to alloantigen disparate stimulators (n = 2
experiments; data not shown). A similar increase in Annexin V binding in CFSElo responder
CD4+ T-cells was seen in PS1145-treated polyclonal B6 anti-bm12 cultures (data not
shown).
PS1145 treatment of alloreactive T-cells significantly reduces their capacity for GVHD
lethality
Our data showed that PS1145 treatment of MLR cultures inhibited primary and secondary
alloresponses in vitro. To determine whether PS1145 treatment of alloreactive T-cells during
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activation would confer reduced capacity for GVHD lethality, sublethally irradiated bm12
recipients were given an adoptive transfer of 105 vehicle or PS1145 cultured (10 µM) B6
CD4+ T-cells. Since previous work from our laboratory has demonstrated a requirement for
CD4+CD25+ regulatory T-cells (Tregs) during ex vivo tolerization protocols by
costimulatory blockade for protection from GVHD (37), we wanted to determine whether
PS1145 induced tolerance also required the presence of Tregs. Studies were performed with
MLR cultures established with either whole CD4+ T-cells or CD4+CD25− T-cells. Uniform
lethality was observed in bm12 recipients by day 18 following adoptive transfer with vehicle
treated CD4+ or CD4+25− T-cells obtained from day 7 MLR cultures (Figure 5A). In
contrast, transfer of the same number of viable PS1145-treated CD4+ or CD4+25− T-cells
recovered from 7-day MLR cutures resulted in 100% or 80% long-term survival rates,
respectively (Figure 5A). These results show that ex vivo PS1145 treatment of alloreactive
T-cells during activation can result in long-term alloantigen tolerance in vivo that is
sufficient to prevent GVHD lethality, irrespective of the presence of CD4+CD25+ T-cells
during tolerization.
As shown in Figure 3, whole T-cells could also be tolerized using PS1145 treatment as
assessed in primary and secondary MLR cultures. To determine if PS1145-treated whole T
cell cultures have decreased GVHD lethality, 105 vehicle or PS1145 (10 µM)-treated CD25−
T-cells obtained from Balb/c anti-B6 day 5 MLR cultures were injected into sublethally
irradiated, NK cell-depleted CB6F1 SCID recipients. As shown in Figure 5B, vehicle-
treated MLR cultures induced GVHD lethality by day 20 post-transfer whereas PS1145-
treated cultures lost their GVHD inducing capability. Thus, PS1145 treatment of MLR
cultured cells was highly effective in preventing GVHD lethality mediated by CD4+,
CD4+25− or CD25− whole T-cells.
PS1145-treated cells have intact immune responses after parking for one month in
lymphopenic syngeneic recipients
A major advantage of ex vivo tolerance induction approaches is the specific targeting of
alloreactive T-cells without affecting non-allospecific T-cells. Because PS1145-treated cells
had impaired secondary alloresponses but intact non-specific mitogen responses in vitro, we
sought to determine whether such tolerized cells could mount an in vivo response to non-
alloantigenic stimulation. Syngeneic Rag-1−/− recipient mice were injected with 2 × 106
vehicle-treated or PS1145-treated (10 µM) CD4+ T-cells obtained from B6 anti-bm12 day 7
MLR cultures. Under these conditions, the only T-cells that would be available for an
immune response in the recipient would be derived from the MLR cultured cells. After 30
days to allow for T cell repopulation and for cells to become quiescent after homeostatic
expansion has been completed, recipient mice were sensitized with 3% oxazolone. Six days
later, mice were rechallenged with 1% oxazolone on the right ear pinna to induce a contact
hypersensitivity (CHS) response. As shown in Figure 6A, Rag-1−/− recipients of PS1145-
treated CD4+ T-cells exhibited significantly more ear swelling than challenged, but
unsensitized B6 control mice or Rag-1−/− recipients without transfer of MLR cells. Because
the CHS response requires T cell activation and recruitment to the site of challenge, this
assay indicates that PS1145-treated cells have retained the capacity to mediate a CD4+
response in vivo, despite their loss in GVHD lethality capacity. These results indicate that
PS1145 treatment and selective targeting of the NF-κB pathway has the capacity to induce
generation of CD4+ T-cells tolerant to alloantigen in vivo but capable of other CD4+ T cell
functions.
Although alloantigen hyporesponsiveness was seen in secondary MLR cultures, it is
possible that the response to potent mitogenic stimuli in vitro were not indicative of
alloantigen-specific tolerance. Therefore, it is possible that the observed CHS responses are
due to a restoration of T cell responses after lymphopenic expansion. To determine if a
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prolonged state of alloantigen-specific hyporesponsiveness could be seen, 2 × 106 freshly
isolated, control- or PS1145-treated day 7 MLR cells (98% inhibition of primary MLR)
were adoptively transferred into Rag-1−/− recipients. After one month, splenic CD4+ T-cells
from each group of mice were transferred into sublethally irradiated bm12 (Figure 6B) or
NK-depleted, sublethally irradiated C3H SCID mice (not shown). All bm12 recipients
succumbed to GVHD induced lethality by day 22 post-transfer. In third party C3H SCID
recipients of control- vs PS1145-treated MLR cells, survival rates were significantly lower
(day 23: 66% vs 100%, respectively; p = 0.05) and there was a statistical trend (p = 0.07)
toward higher mean weight curves. Together, these data indicate that lymphopenic
expansion permits the restoration of immune responses in PS1145-treated MLR cells and
suggests that immune deviation and/or suppression contributes to the reduced GVHD
lethality capacity of freshly infused day 7, PS1145-treated MLR cells given to host-type
recipients.
Discussion
Our studies indicate that ex vivo inhibition of the NF-κB pathway is a new target that
impairs alloreactivity of donor T-cells but can preserve other T cell functions in vitro and in
vivo. These data suggest that the preferential effect of PS1145 on alloreactive versus naïve
non-alloresponsive CD4+ T-cells is dependent upon T cell activation during PS1145
exposure. Because TCR activation pathways are linked to cytokine production and cell
survival pathways via NF-κB signaling, selective inhibition of NF-κB activation in
alloreactive cells that are stimulated by antigen in MLR cultures results in impaired cytokine
production and increased susceptibility to apoptosis. In addition, disconnecting TCR
activation from proliferation (cell cycle progression) and cytokine production is thought to
result in anergy (18). Activated alloreactive cells that are able to survive the minimal
cytokine (especially IL-2 containing) environment and restricted proliferation that follows
PS1145 treatment therefore likely become hyporesponsive. Secondary responses of PS1145
MLR cultures prepared from CD4+ T-cells could be restored to control responses at later
time points using exogenous IL-2 (Figure 2B). These findings suggest that PS1145 treatment
induces hyporesponsiveness in CD4+ T-cells that can be reversed by exogenous IL-2. In
contrast, the addition of IL-2 to secondary whole T cell MLR cultures did not increase
proliferation in PS1145-treated cells. Thus, cultures that also include CD8+ T-cells have a
different mechanism for hyporesponsiveness that may result from efficient deletion of
alloreactive T-cells, immune deviation, or residual PS1145 biological effects in T-cells that
persist in the priming phase of secondary MLR cultures.
The fraction of T-cells in the MLR culture that do not recognize alloantigen and thus do not
have TCR activation appears largely unaffected by PS1145 treatment as measured by
responses to mitogenic stimuli in vitro and nominal antigen challenge in vivo. These cells
likely remain unaffected because they do not have a biochemical requirement for NF-κB
induced cytokine production and survival pathways that would occur in T-cells that have
received an initial potent TCR signal. Alternatively, the potent mitogenic stimuli used in
these assays (anti-3/CD28 mAb coated microbeads) was sufficient to overcome the
hyporesponsiveness of PS1145 treatment. Consistent with the latter hypothesis, CD4+ T cell
responses could be intermittently observed in secondary MLR cultures despite profound
primary MLR responses (data not shown), which we hypothesize may be due to differences
in intracellular PS1145 metabolism or the TCR signal strength that may vary with allo-MLR
stimulator cells between experiments. More importantly, the one month parking of control-
or PS1145- treated MLR cells in lymphopenic syngeneic recipients not only resulted intact
CHS responses but permitted the uniform GVHD lethality capacity of splenic CD4+ T-cells
adoptively transferred into sublethally irradiated secondary recipients (Figure 6B). These
data are consistent with studies demonstrating that homeostatic proliferation results in a
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dominant resistance to tolerance induction (38) and suggest that full tolerance induction by
PS1145 treatment of MLR cells may require a resting state in which T-cells are not driven to
expand by inflammatory stimuli and the accumulation of cytokines that signal T-cells via the
IL-2R common gamma chain. Alternatively, the transfer of day 7, PS1145-treated MLR
cells may result in a temporary state of immune deviation or suppression due to intracellular
concentrations of PS1145 sufficient to transiently inhibit NF-κB translocation and blunt the
immune response, which is restored sometime during the one month parking period in
syngeneic lymphopenic recipients. Such an approach still may be advantageous at
preventing early GVHD induced lethality, while subsequently permitting mature T cell
immune responses to return after the acute period of GVHD risk.
The effects of PS1145 on antigen-activated cells are similar to that of the proteasome
inhibitor Bortezomib, which may inhibit NF-κB pathway activation due to impaired
degradation of IκB. It is tempting to speculate that specific inhibition of the NF-κB pathway
in vivo during the early post-transplant stage when alloreactive donor T-cells become
activated would also result in GVHD inhibition. Consistent with this hypothesis,
administration of Bortezomib resulted in apoptosis of activated alloreactive cells which was
sufficient to prevent GVHD in mice following BMT while anti-tumor responses and donor
engraftment were maintained (12). However, there is a narrow time window for Bortezomib
administration in rodent GVHD models such that the delayed administration of Bortezomib
can markedly increase, rather than reduce, GVHD lethality (12,39,40). How the timing of
Bortezomib administration in rodent models will precisely translate to human allogeneic
BMT is unknown. Moreover, although one study reported that PS1145 administration early
post-BMT protected mice against GVHD lethality (41), in vivo PS1145 administration is
subject to the same critical post-BMT timing issues as Bortezomib (JSS, unpublished data).
If the acute toxicities seen with extended Bortezomib or PS1145 treatment are due to the
release of pro-inflammatory cytokines and tissue injury caused by the conditioning regimen,
it is possible that Bortezomib and NF-κB inhibitors given in vivo later post-BMT with
delayed lymphocyte infusions would be highly effective at preventing GVHD-induced
lethality when these insults would have subsided. Nonetheless, because of the difficulty in
monitoring tolerance induction, controlling antigenic exposure during tolerization and drug-
related toxicities, an efficient ex vivo tolerance induction approach would be favorable to an
in vivo administration of pharmacological agents for prevention of GVHD in the early post-
BMT period.
Previous work by our group and others have shown that activation of alloreactive cells in the
presence of costimulatory blockade or immunesuppressive cytokines may provide a means
to generate a tolerized population of alloreactive T-cells which are impaired in causing
GVHD (9,10). These approaches required the presence of donor CD4+CD25+ Tregs for
tolerance induction (37), whereas PS1145 induced hyporesponsiveness does not. In certain
clinical settings the presence or availability of functional donor Tregs may be limiting such
as following chemotherapy treatment of the recipient or the use of denileukin diftitox to
reduce Tregs in vivo. Therefore, strategies that directly induce tolerance in CD4+ T-cells
may be advantageous by being independent of the presence of Tregs and perhaps by being
more stable after in vivo adoptive transfer, when Tregs and responding T-cells may no
longer be in physical contact.
In summary, we have shown that targeting of the NF-κB pathway can be a highly effective
means of inducing donor anti-host hyporesponsiveness. Ex vivo tolerization of donor T-cells
with PS1145 can induce long-term alloantigen-specific tolerance that is sufficient to
significantly decrease GVHD lethality across MHC barriers while a non-alloreactive CD4+
T cell response can be maintained in vivo. The use of drugs to inhibit NF-κB activation in
this setting may therefore have clinical advantages over more globally immunosuppressive
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strategies. Thus, PS1145 and other drugs designed to specifically inhibit NF-κB pathway
activation in alloreactive cells provide a new clinically applicable strategy for the prevention
of GVHD.
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PS1145 inhibits NF-κB activation and proliferation of alloreactive T-cells in MLR cultures.
(A) p65 nuclear localization is inhibited with increasing concentrations of PS1145. p65
nuclear localization was assessed in anti-CD3/anti-CD28 mAb stimulated CD4+ T-cells that
were treated with vehicle or PS1145. Rabbit anti-p65 mAb and Cy3-conjugated donkey anti-
rabbit mAb were used to visualize p65 by confocal microscopy. (B) B6 anti-bm12 MLR
cultures were established with vehicle control or the indicated concentrations of PS1145.
Proliferation was measured by 3H-thymidine incorporation on the indicated days. Control
versus PS1145 (6 and 10 µM) p<0.05. Each data point represents mean ± SEM. Data are
representative of 3 experiments. (C) p65 binding is inhibited in PS1145-treated (10 µM)
O’Shaughnessy et al. Page 13













primary MLR cultures. Nuclear extracts from day 7 MLR cultures were incubated with
labeled NF-κB consensus sequence probe. DNA-protein complexes were separated by
PAGE and visualized by autoradiography using a p65 specific Ab or whole protein content
in nuclear extracts were visualized by Coomassie blue staining. β-actin Western blot
analysis was used as an additional control. (D) Maximal inhibition of alloresponses requires
treatment PS1145 treatment of CD4+ T-cells and APCs. Purified CD4+ T-cells and APCs
were pre-treated with 10 µM PS1145 or vehicle separately for 30 minutes and washed prior
to initiation of MLR cultures. Proliferation was measured on the indicated days and
expressed as mean CPM ± SEM.
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PS1145 induces alloantigen-specific tolerance in CD4+ T-cells in a MHC class II mismatch
model that is reversed by the addition of exogenous IL-2. (A) B6 anti-bm12 MLR cultures
were established and treated with vehicle or 6 µM PS1145. Proliferation was measured
by 3H-thymidine incorporation on the indicated days. Day 7 MLR cultured cells were
extensively washed and equal numbers of viable cells were re-stimulated with irradiated
bm12 stimulators in the absence or presence of 100 U/ml recombinant human IL-2 (B) or
anti-CDε/anti-CD28 coated beads (C) at a 1:1 ratio. At all time points measured, secondary
alloresponses were inhibited by at least 80% (p<0.0001). Data are from one of three
replicate experiments with similar results.
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PS1145 induces alloantigen-specific tolerance in combined CD4+ and CD8+ T cell cultures
in a complete MHC mismatch model. (A) Balb/c anti-B6 MLR cultures were established
and treated with vehicle or 10 µM PS1145. Proliferation was measured by 3H-thymidine
incorporation on the indicated days. (B) Day 5 MLR cultured cells were extensively washed
and equal numbers of viable cells were re-stimulated with irradiated B6 stimulators at a 1:1
ratio the absence or presence of 100 U/ml recombinant human IL-2 or (C) anti-CD3ε/anti-
CD28 coated beads at a 1:3 ratio. Representative data from three experiments are shown.
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PS1145 selectively induces hyporesponsiveness and apoptosis in antigen-activated T-cells.
Balb/c anti-B6 MLR cultures were established using CFSE-labeled responder T-cells and
assessed for Annexin V binding on day 6 of MLR. Representative data from two
experiments are shown.
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PS1145 treatment of alloreactive T-cells significantly reduces their capacity for GVHD
lethality in primary host-type recipients. (A) 105 vehicle-cultured cells or PS1145 cultured
(10 µM) cells recovered from B6 anti-bm12 day 7 from MLR cultures established with
whole CD4+ T-cells or CD4+CD25− T-cells and injected into sublethally irradiated bm12
recipients (n=5 to 10/group). (B) 105 vehicle-cultured cells or PS1145-cultured (10 µM)
cells recovered on Balb/c anti-B6 day 5 from MLR cultures established with whole CD25−
T-cells and injected into sublethally irradiated CB6F1 SCID recipients (vehicle n=8,
PS1145-treated n=16, p=9.24×10−7).
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Contact hypersensitive responses and GVHD lethality capacity of PS1145-treated day 7
MLR (B6 anti-bm12) cultured cells is intact after one month parking in syngeneic,
lymphopenic Rag-1−/− recipients. (A) 2 × 106 day 7 MLR cultured (10 µM) CD4+ cells
were injected into syngeneic Rag-1−/− recipient mice. After 30 days, recipient mice were
sensitized with 3% oxazolone on thoracic and abdominal skin. Mice were re-challenged 6
days later on the right ear with 1% oxazolone to induce CHS. Swelling in the right ear was
measured at 24 and 96 hours post-challenge. Results of one of two similar experiments are
shown (3–5 mice/experiment). * denotes significance compared to unprimed control
(p<0.05); (B) 2 × 106 fresh, control- or PS1145 (10 µM)-treated, day 7 MLR (B6 anti-bm12)
cultured CD4+ cells were injected into syngeneic Rag-1−/− recipient mice. After 30 days,
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splenic CD4+ T cells were isolated and given to 6 Gy TBI conditioned bm12 recipients (n =
6–8/group). No significant differences were noted in the survival rates between groups.
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